Literature DB >> 11149743

Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia.

R P Howrey1, P L Martin, T Driscoll, P Szabolcs, T Kelly, E J Shpall, S I Bearman, V Slat-Vasquez, P Rubinstein, C E Stevens, J Kurtzberg.   

Abstract

A 15-year-old female received an unrelated three of six HLA antigen matched umbilical cord blood (UCB) transplant for refractory, relapsed T-cell ALL. Conditioning consisted of TBI, melphalan, and anti-thymocyte globulin (ATG), with cyclosporin A (CsA) and solumedrol for GVHD prophylaxis. She engrafted and a day 34 bone marrow aspirate showed 100% donor cells and no evidence of leukemia. The post-transplant course was complicated by mild grade I acute GVHD involving skin, and limited chronic GVHD of the gut which resolved with the addition of 1 mg/kg/day of steroids to her CsA prophylaxis. One hundred and ninety days after transplantation the patient developed pancytopenia and was subsequently found to have a leukemic relapse. Immunosuppression was discontinued and she was started on G-CSF and erythropoietin. Moderate skin and gut GVHD developed which was treated with both topical and low-dose oral steroids. Over the next few weeks she became transfusion independent and a follow-up bone marrow aspirate showed complete remission. She continued in complete remission for 4 months, at which time localized leukemic relapse was found in a soft tissue breast mass in spite of continued bone marrow remission. While the patient ultimately died of progressive disease, this case demonstrates that mismatched UCB in conjunction with G-CSF is capable of generating a GVL effect that can induce a complete remission.

Entities:  

Mesh:

Year:  2000        PMID: 11149743     DOI: 10.1038/sj.bmt.1702697

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Authors:  Patrick J Hanley; Conrad Russell Cruz; Elizabeth J Shpall; Catherine M Bollard
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

Review 2.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

3.  Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.

Authors:  Ikumi Kasahara; Mitsufumi Nishio; Satoshi Yamamoto; Tomoyuki Endo; Katsuya Fujimoto; Keisuke Yamaguchi; Yukari Takeda; Hideki Goto; Norihiro Sato; Takao Koike
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

4.  Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood following a Second Relapse.

Authors:  Suk-Young Lee; Naoki Kurita; Koichiro Maie; Masanori Seki; Yasuhisa Yokoyama; Kazumi Suzukawa; Yuichi Hasegawa; Shigeru Chiba
Journal:  Case Rep Hematol       Date:  2014-02-09

Review 5.  Complete response of extramedullary relapse in breast of acute T lymphoblastic leukemia after bone marrow transplantation to chemoradiotherapy: a case report and literature review.

Authors:  Bailong Liu; Bin Liu; Xu Wang; Liang Guo; Xiaoliang Liu; Wei Han; Lihua Dong; Min Liu
Journal:  BMC Cancer       Date:  2016-11-09       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.